


GLL398

| | |
|---------------------------|---|
| Cat. No.: | HY-101119 |
| CAS No.: | 2077980-80-2 |
| Molecular Formula: | C ₂₅ H ₂₃ BO ₄ |
| Molecular Weight: | 398.26 |
| Target: | Estrogen Receptor/ERR |
| Pathway: | Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (627.73 mM; Need ultrasonic)

| Concentration | Mass | | | |
|---------------|-----------|------------|------------|--|
| | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5109 mL | 12.5546 mL | 25.1092 mL | |
| 5 mM | 0.5022 mL | 2.5109 mL | 5.0218 mL | |
| 10 mM | 0.2511 mL | 1.2555 mL | 2.5109 mL | |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

GLL398, an orally active selective estrogen receptor degrader (SERD), competitively binds to the estrogen receptor with an IC₅₀ value of 1.14 nM. GLL398 exhibits a strong dose-dependent binding profile for the ER with a Y537S point mutation (IC₅₀=29.5 nM). GLL398 blocks tumor growth in xenograft breast cancer models^[1].

In Vitro

GLL398 is a boron-modified GW5638 analog^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Guo S, et al. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models. *Breast Cancer Res Treat.* 2020;180(2):359-368.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA